// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

EAACI task force logograms: Asthma logogram to facilitate the diagnosis of asthma in primary care

Kocks J - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Evolution of airway inflammation in preschoolers with asthma—results of a two‐year longitudinal study

Xepapadaki P - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Automated measurement of MPO and NGAL in nasal mucosal lining fluid

Pertsinidou E - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

IL‐6 and Ykl‐40 in severe asthma

Castro MCE - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Evaluating the validity of a smartphone step‐counter in adults with asthma: A proof‐of‐concept study

Reilly C - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Characteristics of patients admitted with asthma attacks in the emergency department of a University Hospital

Brinia A - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Depression

N/A

Physical in‐activity: Lacking inspiration to exercise?

Price OJ - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

SK1211

Auto‐immunity to C1q: A marker of a subset of idiopathic angioedema

Monnickendam A - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

C1 Inhibitor Deficiency

N/A

Telangiectasia macularis eruptiva perstans

Murryam S - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

N/A

Manuka honey activates the aryl hydrocarbon receptor and down‐regulates IL4‐induced CCL26

Alangari AA - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

IL-4

The Hidden Danger of “Miracle” Creams for Childhood Eczema

Halton FF - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

N/A

Real world experience of using dupilumab to treat eczema endotypes

Mcguire N - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Atopic Dermatitis

Dupilumab

Pseudoephedrine induced baboon syndrome confirmed by oral provocation test

Bisconti I - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

Pseudoephedrine Hydrochloride

Drug hypersensitivity (DH) logograms: Diagnostic and management decision support tools in primary care to optimize healthcare pathways

Gaudin C - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Omalizumab responders analysis in nasal polyposis: A supplementary analysis of the co‐primary endpoints of POLYP 1 and POLYP 2 trials

Corren J - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Omalizumab

IL‐25R‐expressing B cells in chronic rhinosinusitis with nasal polyps

Abdu S - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

IL-4

Seasonal trend of food‐related anaphylaxis hospital admissions in England

Lam HCY - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

N/A

TDA toolkit: Oral food challenges Threshold Data Analysis suite, a web‐based application to derive threshold dose distribution and eliciting doses

Javed B - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Quinoa allergy: A case series

Thomas I - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

Epinephrine

Comparison of protocols for introducing tree nuts in patients with allergy to tree nuts (re‐introducing nuts in allergic patients‐ReINA study) ‐ preliminary data

Pasioti M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved